What We're Reading: Page 378
Industry reads hand-picked by our editors
Nov 12, 2014
-
Wall Street Journal
Specter of antitrust charges looms as Justice Department probes generic price hikes
-
-
Swing and a miss: Merck's ambitious 4-week hep C regimen fails
-
-
Amgen gets PDUFA date for hotly anticipated PCSK9 anti-cholesterol drug
-
-
Pfizer: Nothing shady about our relationship with Missouri Attorney General
-
Cigna responds to discrimination claims with cheaper HIV meds in Florida
-
-
Best of BD: Is the current antibiotic pipeline really that bad? [INFOGRAPHIC]
Nov 11, 2014
-
The cost of a cure: $188B to treat all US hep C patients with pricey new drugs
-
-
Advocates slam protracted UK negotiations over Novartis meningitis B vaccine
-
Salix Pharmaceuticals' inventory woes ruined potential Allergan buyout
-
Political unrest in Russia nixes deal with German pharma company
-
-
-
-
Isis Pharma wins $10M neurodegeneration treatment milestone from Biogen
-
Nov 10, 2014
-
This billionaire hedge fund manager may sue over busted AbbVie-Shire deal
-
-
Ranbaxy loses $250M while US consumers lose a Nexium generic
-
-
FDA approves JNJ's Olysio in combo with Sovadi for hep C treatment
-
-
Allergan, Actavis talk merger while Valeant gets the cold shoulder
-
-
FDA sends Sciecure Pharma rare, scathing letter over insomnia drug sales aid
-
Nov 07, 2014
-
-
-
AZ's $2B ovarian cancer drug-in-development could be a 2-for-1 deal
-
-
-
Why GSK's promising hep C vaccine is good news for its Ebola drug
-
FDA presents novel plan for testing and fast-tracking Ebola drugs
-
-
Largest US pharma benefits manager may seek alcohol/tobacco-free network
-
AstraZeneca lifts 2014 forecast, but how will it deal with Nexium patent expiration?
Nov 06, 2014
-
Innovation in fixed-dose combos: HIV/AIDS therapeutics edition
-
-
-
Lundbeck's schizophrenia drug wallops competition in novel head-to-head trial
-
-
-
-
Allergan-Valeant standoff rages on as Allergan loses in court
-
Regeneron posts solid Q3 on Eylea strength
-
Some payments exempt from Sunshine Act pharma database reporting
Nov 05, 2014
-
RAND study: Biosimilars could save US $44 billion in 10 years
-
-
One-fifth of all drug sales in 2020 could be for pricey, specialty orphan meds
-
-
India-based Wockhardt's profits plummet as it faces continued FDA export ban
-
-
Diagnostics giant LabCorp buys CRO Covance for $6.1 billion
-
-
-
BMS gets heat from advocates over pricing plan for its hep C drug
Nov 04, 2014
-
Express Scripts gearing up to snub Gilead in favor of AbbVie hep C drug
-
-
Feds probe whether US officials engaged in insider trading over Dendreon drug
-
-
Most UK diabetes patients fall short of evidence-based treatment goals
-
-
FDA panel endorses approval of Daaichi's blood clot, stroke drug
-
-
Uh-oh: 2/3 of UK docs defying new statin guidelines
-
Previous
